Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
Status:
Recruiting
Trial end date:
2022-07-16
Target enrollment:
Participant gender:
Summary
The study hypothesis is that new imaging agents [203Pb]VMT01 and [68Ga]VMT02 can be safely
used in humans without independent biological effect and can be used to image melanoma tumors
expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging
modalities respectively.